

Radiopharmaceutical Portfolio Gaps in Big Pharma (Therapeutics)

 Portfolio gap

Company	Commercial	Late-Stage Development (Ph3+)	Early-Stage Development
 abbvie			
 AMGEN			
 AstraZeneca			FPI-2265, FPI-1434, FPI-2059, FPI-2068
 Bristol Myers Squibb		RYZ101 (Ac-225)	RYZ801 (Ac-225), Undisclosed CA9 Asset
 Daiichi-Sankyo			
 Lilly		PNT2002 (Lu-177), PNT2003 (Lu-177)	PSMA-62 (Ac-225), PNT2004 (Lu-177 / Ac-225), PNT2001 (Ac-225), PNT6555 (Lu-177)
 GILEAD			
 GSK			
 Janssen			JNJ-6420 (Ac-225)
 MERCK			
 NOVARTIS	Pluvicto (Lu-177), Lutathera (Lu-177)		Integrin (AA604), 177Lu-NeoB, 225Ac-PSMA-617, 225Ac-PSMA-R2, 177Lu-FAP-2268 (AA614), MC339 (Ac-225)
 Pfizer			
 Roche			

Note: As of 10/29/2024, *non-exhaustive*, excludes GSK's Bexxar; focused on therapeutics, not diagnostics

Andrew Pannu  @andrewpannu

Powered By **Sleuth Insights**